VEN is the first selective BCL2 inhibitor, as well as the first of a new class of anticancer drugs to be approved for routine clinical practice, currently in chronic lymphocytic leukemia and AML.[125] The BCL2 inhibitor VEN enhances the apoptosis and accelerates cell‐autonomous killing induced by CC‐90009 in FLT3‐ internal tandem duplication AML cell lines. Here, BCL2 is linked to acute myeloid leukemia.